Jazz Pharmaceuticals vs Neurocrine Biosciences
JAZZ and NBIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and NBIX compare
Jazz Pharmaceuticals and Neurocrine Biosciences are about the same size, with market caps of $14.0B and $14.9B.
On earnings, Jazz Pharmaceuticals is cheaper: it trades at 14.8× trailing earnings, against 21.4× for Neurocrine Biosciences.
Neurocrine Biosciences grew revenue faster over the last twelve months (34.4% versus 12.6% for Jazz Pharmaceuticals).
Neurocrine Biosciences keeps more of each dollar of sales as profit, with a net margin of 20.9% compared with 20.4% at Jazz Pharmaceuticals.
Neurocrine Biosciences scores higher on the StockData Score (19 against 11 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | NBIX |
|---|---|---|
| Size and price | ||
| Market cap | $14.0B | $14.9B |
| Share price | $215.98 | $146.10 |
| Change, 1 year | 59.1% | 5.9% |
| Change, 5 years | 59.9% | 56.7% |
| Beta (5Y) | 0.55 | 0.49 |
| Employees | 2,890 | 1,800 |
| StockData Score | ||
| Total score | 11 | 19 (better) |
| Valuation score | 4 (better) | 3 |
| Growth score | 1 | 5 (better) |
| Performance score | 4 | 5 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 14.8× (better) | 21.4× |
| P/S | 3.0× (better) | 4.4× |
| P/B | 2.9× (better) | 4.0× |
| EV/EBITDA | 18.0× (better) | 18.2× |
| P/FCF | 8.8× (better) | 17.1× |
| PEG | – | 0.49 |
| FCF yield | 11.4% (better) | 5.9% |
| Fair value | $254.92 | $177.51 |
| Margin of safety | 15.3% | 17.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.6% | 34.4% (better) |
| Revenue growth, 5Y average | 12.5% | 22.3% (better) |
| Net income growth (TTM) | – | 103% |
| EPS growth (TTM) | – | 102% |
| EPS growth, 5Y average | – | 2.3% |
| Profitability | ||
| Gross margin | – | 98.0% |
| Operating margin | 19.5% | 23.6% (better) |
| Net margin | 20.4% | 20.9% (better) |
| FCF margin | 34.6% (better) | 25.8% |
| Return on equity | 22.1% (better) | 22.1% |
| Return on invested capital | 12.1% | 23.7% (better) |
| Financial health | ||
| Debt / equity | 0.91 (better) | 0.00 |
| Net debt / EBITDA | 2.40 | – |
| Current ratio | 1.78 | 1.87 (better) |
| Altman Z-score | 2.35 | 6.83 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.84% |
| Shareholder yield | 0.00% (better) | −0.84% |
| Ownership | ||
| Held by institutions | 99.2% | 99.5% |
| Held by insiders | 3.4% | 1.2% |
| Insider net buying, 12 months | −$68.0M (better) | −$77.9M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 8.7% | 5.8% |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- NBIX stock overview
- NBIX income statement
- NBIX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.